Literature DB >> 19814670

Predicting recurrent stroke after minor stroke and transient ischemic attack.

Philippe Couillard1, Alexandre Y Poppe, Shelagh B Coutts.   

Abstract

The risk of a subsequent stroke following an acute transient ischemic attack or minor stroke is high, with 90-day risk at approximately 10%. Identification of those patients at the highest risk for recurrent stroke following a transient ischemic attack or minor stroke may allow risk-specific management strategies to be implemented, such as hospital admission with expedited work-up for those at high risk and emergency room discharge for those at low risk. Predictors of recurrent stroke, including the ABCD2 score, brain imaging and the stroke mechanism, are reviewed in this article, with a focus on recent literature. An emphasis is placed on the importance of early imaging of the brain parenchyma (diffusion-weighted imaging) and vascular imaging to identify patients at high risk for recurrence. The need for identification of the cause of the initial event, allowing therapies to be tailored to the individual patient, is discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19814670     DOI: 10.1586/erc.09.105

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  3 in total

Review 1.  Diagnosis and Management of Transient Ischemic Attack.

Authors:  Shelagh B Coutts
Journal:  Continuum (Minneap Minn)       Date:  2017-02

2.  Protection against recurrent stroke with resveratrol: endothelial protection.

Authors:  Darren Clark; Ursula I Tuor; Roger Thompson; Adam Institoris; Angela Kulynych; Xu Zhang; David W Kinniburgh; Ferenc Bari; David W Busija; Philip A Barber
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

3.  Exogenous S1P Exposure Potentiates Ischemic Stroke Damage That Is Reduced Possibly by Inhibiting S1P Receptor Signaling.

Authors:  Eunjung Moon; Jeong Eun Han; Sejin Jeon; Jong Hoon Ryu; Ji Woong Choi; Jerold Chun
Journal:  Mediators Inflamm       Date:  2015-10-20       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.